Literature DB >> 17901744

Lymphedema: a comprehensive review.

Anne G Warren1, Håkan Brorson, Loren J Borud, Sumner A Slavin.   

Abstract

BACKGROUND: Lymphedema is a chronic, debilitating condition that has traditionally been seen as refractory or incurable. Recent years have brought new advances in the study of lymphedema pathophysiology, as well as diagnostic and therapeutic tools that are changing this perspective.
OBJECTIVE: To provide a systematic approach to evaluating and managing patients with lymphedema.
METHODS: We performed MEDLINE searches of the English-language literature (1966 to March 2006) using the terms lymphedema, breast cancer-associated lymphedema, lymphatic complications, lymphatic imaging, decongestive therapy, and surgical treatment of lymphedema. Relevant bibliographies and International Society of Lymphology guidelines were also reviewed.
RESULTS: In the United States, the populations primarily affected by lymphedema are patients undergoing treatment of malignancy, particularly women treated for breast cancer. A thorough evaluation of patients presenting with extremity swelling should include identification of prior surgical or radiation therapy for malignancy, as well as documentation of other risk factors for lymphedema, such as prior trauma to or infection of the affected limb. Physical examination should focus on differentiating signs of lymphedema from other causes of systemic or localized swelling. Lymphatic dysfunction can be visualized through lymphoscintigraphy; the diagnosis of lymphedema can also be confirmed through other imaging modalities, including CT or MRI. The mainstay of therapy in diagnosed cases of lymphedema involves compression garment use, as well as intensive bandaging and lymphatic massage. For patients who are unresponsive to conservative therapy, several surgical options with varied proven efficacies have been used in appropriate candidates, including excisional approaches, microsurgical lymphatic anastomoses, and circumferential suction-assisted lipectomy, an approach that has shown promise for long-term relief of symptoms.
CONCLUSIONS: The diagnosis of lymphedema requires careful attention to patient risk factors and specific findings on physical examination. Noninvasive diagnostic tools and lymphatic imaging can be helpful to confirm the diagnosis of lymphedema or to address a challenging clinical presentation. Initial treatment with decongestive lymphatic therapy can provide significant improvement in patient symptoms and volume reduction of edematous extremities. Selected patients who are unresponsive to conservative therapy can achieve similar outcomes with surgical intervention, most promisingly suction-assisted lipectomy.

Entities:  

Mesh:

Year:  2007        PMID: 17901744     DOI: 10.1097/01.sap.0000257149.42922.7e

Source DB:  PubMed          Journal:  Ann Plast Surg        ISSN: 0148-7043            Impact factor:   1.539


  111 in total

1.  Preliminary development of a lymphedema symptom assessment scale for patients with head and neck cancer.

Authors:  Jie Deng; Sheila H Ridner; Barbara A Murphy; Mary S Dietrich
Journal:  Support Care Cancer       Date:  2011-11-10       Impact factor: 3.603

2.  Vascular endothelial growth factor-C enhances radiosensitivity of lymphatic endothelial cells.

Authors:  Cristina T Kesler; Angera H Kuo; Hon-Kit Wong; David J Masuck; Jennifer L Shah; Kevin R Kozak; Kathryn D Held; Timothy P Padera
Journal:  Angiogenesis       Date:  2013-11-08       Impact factor: 9.596

Review 3.  Mechanisms of obesity and related pathologies: the macro- and microcirculation of adipose tissue.

Authors:  Joseph M Rutkowski; Kathryn E Davis; Philipp E Scherer
Journal:  FEBS J       Date:  2009-09-15       Impact factor: 5.542

Review 4.  Management of secondary lymphedema related to breast cancer.

Authors:  Oren Cheifetz; Louise Haley
Journal:  Can Fam Physician       Date:  2010-12       Impact factor: 3.275

5.  A comparison of the effectiveness of complex decongestive physiotherapy and stellate ganglion block with triamcinolone administration in breast cancer-related lymphedema patients.

Authors:  Jeong-Gil Kim; Soon Ook Bae; Kwan Sik Seo
Journal:  Support Care Cancer       Date:  2015-01-11       Impact factor: 3.603

6.  Timing of Lymphedema After Treatment for Breast Cancer: When Are Patients Most At Risk?

Authors:  Susan G R McDuff; Amir I Mina; Cheryl L Brunelle; Laura Salama; Laura E G Warren; Mohamed Abouegylah; Meyha Swaroop; Melissa N Skolny; Maria Asdourian; Tessa Gillespie; Kayla Daniell; Hoda E Sayegh; George E Naoum; Hui Zheng; Alphonse G Taghian
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-08-28       Impact factor: 7.038

7.  Regulatory T cell transfer ameliorates lymphedema and promotes lymphatic vessel function.

Authors:  Epameinondas Gousopoulos; Steven T Proulx; Samia B Bachmann; Jeannette Scholl; Dimitris Dionyssiou; Efterpi Demiri; Cornelia Halin; Lothar C Dieterich; Michael Detmar
Journal:  JCI Insight       Date:  2016-10-06

Review 8.  Mechanical forces in lymphatic vascular development and disease.

Authors:  Lara Planas-Paz; Eckhard Lammert
Journal:  Cell Mol Life Sci       Date:  2013-05-12       Impact factor: 9.261

9.  Factors predicting adherence to risk management behaviors of women at increased risk for developing lymphedema.

Authors:  Kerry A Sherman; Suzanne M Miller; Pagona Roussi; Alan Taylor
Journal:  Support Care Cancer       Date:  2014-06-27       Impact factor: 3.603

10.  Diphtheria toxin-mediated ablation of lymphatic endothelial cells results in progressive lymphedema.

Authors:  Jason C Gardenier; Geoffrey E Hespe; Raghu P Kataru; Ira L Savetsky; Jeremy S Torrisi; Gabriela D García Nores; Joseph J Dayan; David Chang; Jamie Zampell; Inés Martínez-Corral; Sagrario Ortega; Babak J Mehrara
Journal:  JCI Insight       Date:  2016-09-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.